Skip to main content
. 2016 Sep 13;47(4):366–374. doi: 10.1007/s12029-016-9866-9

Fig. 2.

Fig. 2

a Schematic view of subcutaneous depot and sustained drug release. Inset shows diffusion of active drug to the adjacent capillaries. b Pharmacokinetic properties and c concentration-time curve of lanreotide depot after a single 120-mg injection in healthy volunteers [5, 6]. C 28 mean serum concentration 28 days after injection, C max peak serum concentration, T max time to reach C max, t 1/2 apparent terminal elimination half-life